Except for the increased CD8+ PD1+ levels in M2 AML patients, there was no significant association between the most common clinical indications and PD-1 expression in ALL and AML patients, indicating that PD-1 expression is not affected by general clinical manifestations and common hematologic indicators. This evidence concerns the gene CD8A and acute myeloid leukemia.